How is neuropathic cancer pain assessed in randomised controlled trials?

摘要: The prevalence of neuropathic cancer pain is estimated to be between 40% and 80% [9,16,26] may directly caused by tumour infiltration or compression (92.5%), chemotherapy, radiotherapy, surgery (20.8%) [9,28]. Neuropathic has long been suggested reduce opioid responsiveness [25] claimed a major prognostic factor for poor control [8]. According the International Association Study Pain, defined as ‘‘pain initiated primary lesion dysfunction in nervous system’’ [22]; however, this definition criticized lack both diagnostic specificity precision [29]. Treede et al. [29] recently presented related abnormal somatosensory processing peripheral and/or central system. Although not free controversy, their arising direct consequence disease affecting provides 4 specific criteria grading certainty diagnosis European Federation Neurological Societies revised guidelines on assessment [11]. They concluded that history bedside examination are still essential correct diagnosis, whereas screening tools questionnaires useful indicating aim study examine used assessing previous published randomized controlled trials (RCTs) advanced cancer.